Abstract:Background Polymerase chain reaction (PCR) assays are perceived to facilitate the diagnosis of fungal infections. However, due to lack of standardization, the value of bronchoalveolar lavage (BAL) fluid PCR in diagnosis of invasive pulmonary aspergillosis (IPA) remains unclear. Methods We conducted a systematic meta-analysis to evaluate the accuracy of BAL fluid PCR in IPA diagnosis among high-risk patients. All studies involving patients at risk for IPA were included. The sensitivity, specificity, positive and negative likelihood ratios of BAL fluid PCR were summarized for diagnosis of proven/probable IPA, or proven IPA only. Potential heterogeneity was assessed by subgroup analyses and meta-regression. Results Forty-one studies involving 5668 patients were analyzed. The summary sensitivity, specificity, positive and negative likelihood ratios of BAL fluid PCR for proven/probable IPA were 0.75 (95% CI = 0.67–0.81), 0.94 (95% CI = 0.90–0.96), 11.8 (95% CI = 7.7–18.1) and 0.27 (95% CI = 0.20–0.36), respectively. Whereas for proven IPA only, sensitivity and specificity were 0.91 (95% CI = 0.68–0.98) and 0.80 (95% CI = 0.74–0.85) in fourteen studies involving 2061 patients. Significant heterogeneity was present due to the underlying disease, antifungal treatment and differences in DNA extraction techniques and choice of PCR assay. Compared to patients with hematological malignancies (HM) and hematopoietic stem cell/solid organ transplantation (HSCT/SOT), sensitivity was higher in the population with disease such as chronic obstructive pulmonary disease, solid tumor, autoimmune disease with prolonged use of corticosteroids, etc. (0.88 vs. 0.68, P < 0.001), which was related to the concurrent use of antifungal prophylaxis among patients with HM and HSCT/SOT. Conclusion BAL fluid PCR is a useful diagnostic tool for IPA in immunocompromised patients and is also effective for diagnosing IPA in patients without HM and HSCT/SOT. Furthermore, standard protocols for DNA extraction and PCR assays should be focused on to improve the diagnostic accuracy. Trial registration PROSPERO, registration number CRD42021239028.

Serum galactomannan test for diagnosis of invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease

Serum Galactomannan Level for the Diagnosis of Invasive Pulmonary Aspergillosis in Hospitalized Patients with Chronic Obstructive Pulmonary Disease (COPD): Meta-analysis

Diagnostic Value of Galactomannan Antigen Test in Serum and Bronchoalveolar Lavage Fluid Samples from Patients with Nonneutropenic Invasive Pulmonary Aspergillosis.

[Serum Antigens Assay Combined with Chest CT Scan in Diagnosis of Invasive Pulmonary Aspergillosis].

The diagnosis of invasive and noninvasive pulmonary aspergillosis by serum and bronchoalveolar lavage fluid galactomannan assay.

Quantitative Real-Time PCR and Platelia Galactomannan Assay for the Diagnosis of Invasive Pulmonary Aspergillosis: Bronchoalveolar Lavage Fluid Performs Better Than Serum in Non-neutropaenic Patients

[The Value of Serum Galactomannan Detection for Diagnosis of Invasive Aspergillosis in Hematopoietic Stem Cell Transplant Recipients].

Performance of the galactomannan test for the diagnosis of invasive pulmonary aspergillosis using non-invasive proximal airway samples

Diagnosis values of IL-6 and IL-8 levels in serum and bronchoalveolar lavage fluid for invasive pulmonary aspergillosis in chronic obstructive pulmonary disease

[Evaluation of the Galactomannan Assay for the Diagnosis of Invasive Aspergillosis in Patients].

A Systematic Review of the Accuracy of Diagnostic Test of Serum Galactomannan Antigen Detection for Invasive Aspergillosis

The clinical value of Aspergillus -specific IgG antibody test in the diagnosis of nonneutropenic invasive pulmonary aspergillosis

Diagnostic Value of Galactomannan in Bronchoalveolar Lavage Fluid for Chronic Respiratory Disease with Pulmonary Aspergillosis

Systematic review and meta-analysis of galactomannan antigen testing in serum and bronchoalveolar lavage for the diagnosis of chronic pulmonary aspergillosis: defining a cutoff

Performance of Lateral Flow Device and Galactomannan for the Detection of Aspergillus Species in Bronchoalveolar Fluid of Patients at Risk for Invasive Pulmonary Aspergillosis

Bronchoalveolar lavage fluid polymerase chain reaction for invasive pulmonary aspergillosis among high-risk patients: a diagnostic meta-analysis

IL-17 in plasma and bronchoalveolar lavage fluid in non-neutropenic patients with invasive pulmonary aspergillosis

Diagnostic value and clinical use of metagenomic next-generation sequencing for invasive pulmonary aspergillosis

Evaluation of a Commercial Quantitative Aspergillus Fumigatus-Specific IgM Assay for the Diagnosis of Invasive Pulmonary Aspergillosis.

Early Diagnosis of Invasive Pulmonary Aspergillosis

[Combination of Real-Time Polymerase Chain Reaction Assay and Serum Galactomannan in the Diagnosis of Invasive Aspergillosis in Patients with Hematological Malignancies and Recipients of Hematopoietic Stem Cell Transplantation].